Harvoni 400mg/90mg (Sofosbuvir,Ledipasvir)
What is Harvoni 400mg/90mg (Sofosbuvir,Ledipasvir) ?
Harvoni 400mg/90mg (Sofosbuvir,Ledipasvir) is an oral tablet containing two drugs used for the treatment of chronic infection with the hepatitis C virus (HCV), genotype 1 in adults.
Harvoni 400mg/90mg (Sofosbuvir,Ledipasvir) belongs to a group of drugs known as antivirals. Both active ingredients in Harvoni prevent the hepatitis C virus from reproducing.
Each orange, diamond-shaped, film-coated tablet debossed with “GSI” on one side and “7985” on the other contains 90 mg of ledipasvir and 400 mg of sofosbuvir. Nonmedicinal ingredients: colloidal silicon dioxide, copovidone, croscarmellose sodium, lactose monohydrate, magnesium stearate, and microcrystalline cellulose; film coating: polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and FD&C Yellow No. 6/Sunset Yellow FCF Aluminum Lake.
Side effects of Harvoni
The following side effects are severe or don’t go away:
Serious Side Effects
While no major side effects of taking Harvoni have been reported, serious side effects are still a possibility.
How to use Harvoni ?
The recommended dose of ledipasvir – sofosbuvir for adults and children, 12 years of age or older and weighing 35 kg or more, is one tablet, taken by mouth, once a day. It may be taken with or without food. You will need to take this medication for 12 or 24 weeks, depending on your personal health history and condition.
If you vomit less than 5 hours after taking the medication, take another dose. If it is more than 5 hours after taking the dose, continue with your regular dosing schedule.
Store this medication in its original package at room temperature. Keep out of reach of children.
Interactions with other drugs
Acid reducing agents which are commonly used to treat heartburn, indigestion, and GERD may decrease the effectiveness of Harvoni treatment by decreasing blood levels of ledipasvir. Examples of acid reducing agents include antacids, histamine 2 receptor antagonists, for example, famotidine (Pepcid), and proton pump inhibitors (PPIs), for example, omeprazole (Prilosec).
Antacid and Harvoni administration should be separated by 4 hours. Doses of histamine 2 receptor antagonists equivalent to famotidine 40 mg twice daily or less and doses of proton pump inhibitors equivalent to 20 mg of omeprazole or lower may be given at the same time as Harvoni.
Co-administration of Harvoni and amiodarone is not recommended because the combination may cause serious heart-related side effects including symptomatic bradycardia.
Anti-seizure medications including carbamazepine (Tegretol), phenytoin (Dilantin), phenobarbital (Luminal), and oxcarbazepine (Trileptal) may increase the breakdown of Harvoni, leading to reduced therapeutic effectiveness.
Taking St. John’s Wort or rifampin with Harvoni may also reduce the effectiveness of treatment and is not recommended.
Certain medication used to treat tuberculosis (TB) infection may decrease the effectiveness of Harvoni treatment. Patients taking rifampin, rifabutin, or rifapentine should consult with their doctor or pharmacist before starting Harvoni.
Co-administration of Harvoni with rosuvastatin (Crestor), a cholesterol lowering medication, may significantly increase the blood concentration of rosuvastatin and increase the risk side effects such as serious muscle injury.